All In Biotech

Drug Trial Radar · NCT05072938

Clinical Trial to Compare Rebamipide/Nizatidine Combination Therapy With Nizatidine Monotherapy in Patients With Gastritis

A Multi-center, Open-label, Randomized, Phase IV Clinical Trial to Compare the Efficacy and Safety of Rebamipide/Nizatidine Combination Therapy With Nizatidine Monotherapy in Patients With Gastritis

Last checked: Nov 20, 2026Latest source record: Jul 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

260

Actual

Start

Sep 30, 2021

Primary completion

Dec 15, 2022

Study completion Dec 15, 2022

Sponsor

Sponsor type
Industry
First posted
Oct 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the Efficacy and Safety of Rebamipide/Nizatidine Combination Therapy with Nizatidine Monotherapy in Patients with Gastritis

Conditions

  • Gastritis

Interventions

  • Mucotra SR Tablet 150mgDrug

    Rebamipide/Nizatidine Combination Therapy

  • Axid Capsule 150mgDrug

    Nizatidine Monotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effective rate of gastric mucosal erosion on the upper gastrointestinal endoscopyTime frame: 2 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Catholic University of Korea c St. Mary's Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.